Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 10;6(6):e1000803.
doi: 10.1371/journal.ppat.1000803.

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

Edward A Berger  1 , Ira Pastan
Affiliations

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

Edward A Berger et al. PLoS Pathog. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

E.A.B. and I.P. are co-inventors on NIH-owned issued patents and patent applications for CD4-PE and 3B3-PE.

Figures

Figure 1
Figure 1. Schematic of Env-targeted toxins based on Pseudomonas exotoxin A.
The immunotoxins are based on the domain organization of native PE (top). The N-terminal segment (domain I) is involved in binding to a surface receptor (members of the low density lipoprotein receptor-related protein 1 family), the central region (domain II) facilitates membrane translocation of the toxin into the cytoplasm, and the C-terminal segment (domain III) catalyzes ADP-ribosylation of elongation factor 2, resulting in shut-down of protein synthesis and cell death. In the recombinant single chain immunotoxins, domain I is replaced by a targeting moiety directed at HIV-1 gp120: soluble CD4 first two domains (CD4-PE, middle), or the 3B3 SCFv (3B3-PE, bottom).
Figure 2
Figure 2. Effects of complementing HAART with Env-targeted toxins in thy/liv SCID-hu mouse model.
Thy/liv-SCID-hu mice were injected intraperitoneally with HIV and either left untreated (None) or immediately started on the indicated treatment. One month later, the left thy/liv implants were biopsied, and viral loads were analyzed by quantitative coculture (open bars). Drug therapy was then stopped, and after 1 month the left thy/liv implant of each mouse was rebiopsied and the viral load quantitated (filled bars). The data are presented as the TCID/106 thymocytes; the mean values (± SEM) were calculated for each group. Left panel, HAART (zidovudine+ lamivudine + ritonavir) or immunotoxins alone; right panel, HAART alone compared to HAART plus immunotoxins. Data adapted from (© 2000 by Goldstein et al.).
See this image and copyright information in PMC

References

    1. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res. 2010;85:1–18. - PMC - PubMed
    1. Contreras X, Lenasi T, Peterlin BM. HIV latency: present knowledge and future directions. Future Virol. 2006;1:733–745. - PMC - PubMed
    1. Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med. 2008;59:487–501. - PubMed
    1. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008;122:22–28. - PMC - PubMed
    1. Stevenson M. Can HIV be cured? Sci Am. 2008;299:78–83. - PubMed

Publication types